Endo Announces Publication of Peyronie's Disease Self-Assessment Screening App Article in Peer-Reviewed Translational Andrology and Urology
Endo (OTCQX: NDOI) announced the publication of their Peyronie's disease (PD) self-assessment screening app in the peer-reviewed journal Translational Andrology and Urology. The app aims to help men document curvature deformities and prepare for urologist visits, addressing the reluctance many face in discussing this intimate condition. The application features include image scans, a self-assessment questionnaire, and a provider locator. The article was authored by healthcare professionals including Gregory A. Broderick, MD, Jesse N. Mills, MD, Lisa Bathish, BA, PMP, Christopher Davis, PMP, and Mohit Khera, MD, MBA, MPH.
Endo (OTCQX: NDOI) ha annunciato la pubblicazione della loro app di auto-valutazione per la malattia di Peyronie (PD) nella rivista peer-reviewed Translational Andrology and Urology. L'app ha l'obiettivo di aiutare gli uomini a documentare le deformità della curvatura e a prepararsi per le visite urologiche, affrontando la riluttanza che molti provano nel parlare di questa condizione intima. Le funzionalità dell'applicazione includono scansioni di immagini, un questionario di auto-valutazione e un localizzatore di fornitori. L'articolo è stato redatto da professionisti della salute tra cui Gregory A. Broderick, MD, Jesse N. Mills, MD, Lisa Bathish, BA, PMP, Christopher Davis, PMP, e Mohit Khera, MD, MBA, MPH.
Endo (OTCQX: NDOI) anunció la publicación de su app de autoevaluación para la enfermedad de Peyronie (PD) en la revista revisada por pares Translational Andrology and Urology. La aplicación tiene como objetivo ayudar a los hombres a documentar las deformidades de curvatura y a prepararse para las visitas con el urólogo, abordando la reticencia que muchos enfrentan al hablar de esta condición íntima. Las funcionalidades de la aplicación incluyen escaneos de imágenes, un cuestionario de autoevaluación y un localizador de proveedores. El artículo fue redactado por profesionales de la salud, incluidos Gregory A. Broderick, MD, Jesse N. Mills, MD, Lisa Bathish, BA, PMP, Christopher Davis, PMP y Mohit Khera, MD, MBA, MPH.
Endo (OTCQX: NDOI)는 동료 심사를 거친 저널인 Translational Andrology and Urology에 페이로니 질환(PD) 자가 평가 스크리닝 앱의 출판을 발표했습니다. 이 앱은 남성들이 곡률 변형을 문서화하고 비뇨기과 의사 방문을 준비하는 데 도움을 주며, 많은 사람들이 이 친밀한 문제에 대해 이야기하는 것에 대해 느끼는 망설임을 해소하는 것을 목표로 합니다. 이 애플리케이션의 기능에는 이미지 스캔, 자가 평가 설문지 및 제공자 찾기 기능이 포함됩니다. 이 기사는 Gregory A. Broderick, MD, Jesse N. Mills, MD, Lisa Bathish, BA, PMP, Christopher Davis, PMP, 및 Mohit Khera, MD, MBA, MPH와 같은 의료 전문가들이 저술했습니다.
Endo (OTCQX: NDOI) a annoncé la publication de leur application d'auto-évaluation pour la maladie de Peyronie (PD) dans la revue peer-reviewed Translational Andrology and Urology. L'application vise à aider les hommes à documenter les déformations de courbure et à se préparer pour les visites chez l'urologue, en abordant la réticence que beaucoup ressentent à parler de cette condition intime. Les fonctionnalités de l'application incluent des scans d'images, un questionnaire d'auto-évaluation et un localisateur de prestataires. L'article a été rédigé par des professionnels de la santé, notamment Gregory A. Broderick, MD, Jesse N. Mills, MD, Lisa Bathish, BA, PMP, Christopher Davis, PMP et Mohit Khera, MD, MBA, MPH.
Endo (OTCQX: NDOI) hat die Veröffentlichung ihrer Selbstbewertungs-App für die Peyronie-Krankheit (PD) in der peer-reviewed Zeitschrift Translational Andrology and Urology angekündigt. Die App soll Männern helfen, Krümmungsdeformitäten zu dokumentieren und sich auf Besuche beim Urologen vorzubereiten, um die Zurückhaltung anzugehen, die viele beim Sprechen über diese intime Erkrankung empfinden. Zu den Funktionen der Anwendung gehören Bildscans, ein Selbstbewertungsfragebogen und ein Anbieter-Standort. Der Artikel wurde von Gesundheitsfachleuten verfasst, darunter Gregory A. Broderick, MD, Jesse N. Mills, MD, Lisa Bathish, BA, PMP, Christopher Davis, PMP und Mohit Khera, MD, MBA, MPH.
- Publication in peer-reviewed journal validates company's medical technology development
- New digital health tool expands company's presence in urology market
- None.
"Men can be reluctant to discuss curvature deformities with healthcare providers due to the intimate nature of the topic and possible embarrassment," said Gregory A. Broderick, MD, urologist and lead author. "The app was designed to give men the resources to confidently document their symptoms, prepare them for a visit with a urologist and take charge of their PD."
The article details the purpose of the PD app, involvement from healthcare providers in the development of the tool and various features of the app, including image scans, a self-assessment questionnaire and provider locator.
"Development of a new Peyronie's disease self-assessment screening app" was submitted by authors Gregory A. Broderick, MD; Jesse N. Mills, MD; Lisa Bathish, BA, PMP; Christopher Davis, PMP; and Mohit Khera, MD, MBA, MPH.
About the App
The Peyronie's disease (PD) self-assessment screening app is a free tool designed to help men learn about PD, track penile curvature and facilitate discussions with healthcare providers. It offers access to Sexual Medicine Society of
The PD self-assessment app has not been evaluated by any regional or national health authority. It is not intended to diagnose, treat, cure, or prevent any medical condition, disease or health problem. Men should consult their physicians for medical advice.
All data remains confidential, stored only within the app on the user's device. The app is available in the App Store and Google Play.
About Peyronie's Disease
Peyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.1 It is estimated that PD can affect as many as 1 in 10 men in the
About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Dr. Broderick and any statements relating to product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, safety or adverse reactions, patient self-assessments, discussions with healthcare providers, confidentiality of information, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which we may not currently be able to predict. Although we believe that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, compliance with regulatory obligations including those under the XIAFLEX REMS Program, unexpected litigation or other disputes, our ability to successfully implement and execute on our strategies and initiatives, and changes in competitive, market or regulatory conditions. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the
References:
- Hellstrom WJ. Int J Impot Res. 2003;15:S91-S92.
- Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.
- DiBenedetti DB, Nguyen D, Zografoset L, al. Adv Urol. 2011:282503
View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-announces-publication-of-peyronies-disease-self-assessment-screening-app-article-in-peer-reviewed-translational-andrology-and-urology-302332150.html
SOURCE Endo, Inc.
FAQ
What features does Endo's (NDOI) new Peyronie's disease screening app include?
When was Endo's (NDOI) Peyronie's disease app study published?
Who are the key authors of Endo's (NDOI) Peyronie's disease app study?
What is the main purpose of Endo's (NDOI) Peyronie's disease screening app?
